<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414359</url>
  </required_header>
  <id_info>
    <org_study_id>207313</org_study_id>
    <nct_id>NCT03414359</nct_id>
  </id_info>
  <brief_title>Comparison of Chloroprocaine vs Lidocaine for Epidural Anesthesia in Cesarean Delivery</brief_title>
  <official_title>A Randomized, Double-blind Study Comparing 3% Chloroprocaine Versus 2 % Lidocaine/ Epinephrine/ Bicarbonate/ Fentanyl for Epidural Anesthesia in Elective Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional anesthesia is commonly used for elective and emergency cesarean delivery. It
      provides numerous safety advantages when compared to general anesthesia for both the mother
      and fetus1. Epidurals also have the added benefit of being able to provide pain relief
      throughout labor and in the event of cesarean delivery, epidural analgesia can be &quot;extended&quot;
      to provide surgical anesthesia. Numerous studies have been performed to assess the onset
      times of various local anesthetics when administered through an epidural catheter. Attempts
      to reduce anesthetic onset time and improve the quality of intraoperative analgesia have been
      attempted by using different local anesthetic solutions and by the addition of other drugs to
      the epidural solution (such as epinephrine, fentanyl and sodium bicarbonate).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regional anesthesia is commonly used for elective and emergency cesarean delivery. It
      provides numerous safety advantages when compared to general anesthesia for both the mother
      and fetus1. Epidurals also have the added benefit of being able to provide pain relief
      throughout labor and in the event of cesarean delivery, epidural analgesia can be &quot;extended&quot;
      to provide surgical anesthesia. Numerous studies have been performed to assess the onset
      times of various local anesthetics when administered through an epidural catheter. Attempts
      to reduce anesthetic onset time and improve the quality of intraoperative analgesia have been
      attempted by using different local anesthetic solutions and by the addition of other drugs to
      the epidural solution (such as epinephrine, fentanyl and sodium bicarbonate).

      A recent meta-analysis concluded that the optimum local anesthetic solution for extending a
      labor epidural from analgesia to surgical anesthesia has yet to be determined 2. In 1994, a
      retrospective study compared 1.5% lidocaine/bicarbonate/epinephrine mixture to 3%
      chloroprocaine in parturients with pre-existing epidural catheters for urgent cesarean
      delivery3. It was found that the chloroprocaine group had a significantly faster onset of
      anesthesia compared to the lidocaine group. Both drugs provided excellent anesthesia. However
      a high quality study comparing 3% chloroprocaine with 2% lidocaine/ epinephrine/ bicarbonate/
      fentanyl (LEBF) in terms of anesthetic onset times has yet to be performed.

      Women in labor frequently request an epidural to provide pain relief. Epidural pain relief is
      commonly provided by the administration of a low concentration of local anesthetic and opioid
      solution through an epidural catheter. This solution is delivered by an automated epidural
      infusion pump. In the event that a cesarean delivery is required, the pre-existing epidural
      is frequently used to administer a higher concentration anesthetic solution to allow pain
      free cesarean delivery. This is commonly referred to as an &quot;epidural top up&quot; or as an
      &quot;extension of the epidural block.&quot; Standard practice at University of Arkansas for Medical
      Sciences (UAMS) for an epidural top up is Lidocaine, Epinephrine, Bicarbonate and Fentanyl
      (LEBF) or 3% chloroprocaine. These two mixtures are routinely and almost exclusively used for
      epidural cesarean delivery. The decision on which mixture to use is based solely on physician
      preference. It is likely that the LBEF mixture is used more frequently but the investigators
      consider both local anesthetic mixtures as equals and the standard of care at UAMS. The
      investigators do not use any other local anesthetics (unless there are very specific
      reasons).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Actual">March 27, 2019</completion_date>
  <primary_completion_date type="Actual">March 27, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Onset Time to Surgical Anesthesia</measure>
    <time_frame>Up to 35 minutes</time_frame>
    <description>The onset time to surgical anesthesia, as reported by the participant using a standard procedure This will be measured by the time taken from the end of the epidural loading dose to develop a loss of touch sensation using a neurotip® (Owen Mumford, USA) device bilaterally at the T7 dermatomal level using a non-inferiority study design. A non-inferiority limit of 3 minutes was chosen apriori.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome: Number of Participants With Requirement for Intraoperative Analgesia Supplementation</measure>
    <time_frame>1 hour</time_frame>
    <description>This requirement for any rescue medications to control discomfort or pain during CD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Surgical Anesthesia, Cesarean Section</condition>
  <arm_group>
    <arm_group_label>2% Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% Chloroprocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% Lidocaine</intervention_name>
    <description>2% Lidocaine using a combined spinal-epidural (CSE)</description>
    <arm_group_label>2% Lidocaine</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% Chloroprocaine</intervention_name>
    <description>3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
    <arm_group_label>3% Chloroprocaine</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age for the mother

          -  Singleton pregnancy

          -  Gestation &gt; 36 weeks

          -  American Society of Anesthesiologist (ASA) class II

          -  Provides written consent

          -  Infant of mother

        Exclusion Criteria:

          -  Patient refusal

          -  Non-elective or urgent/emergent cesarean sections

          -  ASA class III or above

          -  Unable to understand English

          -  Significant back surgery or scoliosis

          -  Known fetal abnormality

          -  Weight &gt; 120 kg

          -  Height &lt; 150 cm

          -  Allergy to local anesthetics

          -  Concurrent use of sulfonamides
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Any mother requiring an elective cesarean section.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadir Sharawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <results_first_submitted>February 12, 2020</results_first_submitted>
  <results_first_submitted_qc>March 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2020</results_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03414359/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2% Lidocaine</title>
          <description>2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)</description>
        </group>
        <group group_id="P2">
          <title>3% Chloroprocaine</title>
          <description>3% Chloroprocaine: 3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2% Lidocaine</title>
          <description>2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)</description>
        </group>
        <group group_id="B2">
          <title>3% Chloroprocaine</title>
          <description>3% Chloroprocaine: 3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="B2" value="30" lower_limit="24" upper_limit="34"/>
                    <measurement group_id="B3" value="28" lower_limit="24" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31" lower_limit="27" upper_limit="37"/>
                    <measurement group_id="B2" value="32" lower_limit="29" upper_limit="37"/>
                    <measurement group_id="B3" value="31" lower_limit="28" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="273" lower_limit="273" upper_limit="275"/>
                    <measurement group_id="B2" value="273" lower_limit="268" upper_limit="273"/>
                    <measurement group_id="B3" value="273" lower_limit="270" upper_limit="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of epidural infusion</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="38" upper_limit="73"/>
                    <measurement group_id="B2" value="49" lower_limit="36" upper_limit="70"/>
                    <measurement group_id="B3" value="49" lower_limit="37" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Onset Time to Surgical Anesthesia</title>
        <description>The onset time to surgical anesthesia, as reported by the participant using a standard procedure This will be measured by the time taken from the end of the epidural loading dose to develop a loss of touch sensation using a neurotip® (Owen Mumford, USA) device bilaterally at the T7 dermatomal level using a non-inferiority study design. A non-inferiority limit of 3 minutes was chosen apriori.</description>
        <time_frame>Up to 35 minutes</time_frame>
        <population>Per protocol analysis</population>
        <group_list>
          <group group_id="O1">
            <title>2% Lidocaine</title>
            <description>2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)</description>
          </group>
          <group group_id="O2">
            <title>3% Chloroprocaine</title>
            <description>3% Chloroprocaine: 3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
          </group>
        </group_list>
        <measure>
          <title>The Onset Time to Surgical Anesthesia</title>
          <description>The onset time to surgical anesthesia, as reported by the participant using a standard procedure This will be measured by the time taken from the end of the epidural loading dose to develop a loss of touch sensation using a neurotip® (Owen Mumford, USA) device bilaterally at the T7 dermatomal level using a non-inferiority study design. A non-inferiority limit of 3 minutes was chosen apriori.</description>
          <population>Per protocol analysis</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558" spread="269"/>
                    <measurement group_id="O2" value="655" spread="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To exclude a clinically important difference between the LEBF group and the chloroprocaine group, given a standard deviation of 4 minutes, and a non-inferiority margin of 3 minutes difference between groups, 62 mother-infant dyads (31 mother-infant dyads in each arm) are required to have a significance level of 5% and a power of 90%. In total, 70 female patients were recruited to account for any withdrawals.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>As there is no existing data in the literature that clearly defines a clinically significant reduction in the onset time of anesthesia, the non-inferiority margin was defined a priori based on clinical reasoning.</non_inferiority_desc>
            <p_value>0.10</p_value>
            <p_value_desc>The a priori threshold for statistical significance is, &lt;0.05</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome: Number of Participants With Requirement for Intraoperative Analgesia Supplementation</title>
        <description>This requirement for any rescue medications to control discomfort or pain during CD</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>2% Lidocaine</title>
            <description>2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)</description>
          </group>
          <group group_id="O2">
            <title>3% Chloroprocaine</title>
            <description>3% Chloroprocaine: 3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome: Number of Participants With Requirement for Intraoperative Analgesia Supplementation</title>
          <description>This requirement for any rescue medications to control discomfort or pain during CD</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During inpatient admission, approximately three days</time_frame>
      <desc>local anesthetic systemic toxicity (LAST), post-dural puncture headache (PDPH) and high spinal (defined as upper limb weakness)</desc>
      <group_list>
        <group group_id="E1">
          <title>2% Lidocaine</title>
          <description>2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)</description>
        </group>
        <group group_id="E2">
          <title>3% Chloroprocaine</title>
          <description>3% Chloroprocaine: 3% Chloroprocaine using a combined spinal-epidural (CSE)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Post dural puncture headache</sub_title>
                <description>presumed post-dural puncture headache due to spinal needle, treated with epidural blood batch</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nadir El Sharawi</name_or_title>
      <organization>UAMS</organization>
      <phone>5016866114</phone>
      <email>nelsharawi@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

